Guangyuyuan Chinese Medicine

Guangyuyuan Chinese Medicine (广誉远中药) is identified in the supplied evidence as a traditional Chinese medicine brand associated with Chinese patent medicines. The evidence does not establish its founding history, corporate ownership, headquarters, product range, or geographic markets. Its listed website is https://www.gyy.com.cn, but no website content was provided to substantiate further details.

The supplied evidence identifies Guangyuyuan Chinese Medicine as a traditional Chinese medicine and Chinese patent medicine brand, but provides no dates or historical details. It does not support claims about the brand’s origin, founders, corporate development, ownership changes, or present operating status. A fuller history cannot be established from the available evidence.

• Guangyuyuan is recognized as a traditional Chinese medicine brand producing 中成药 (Chinese patent medicines).

A traditional Chinese medicine brand; the evidence does not establish a more specific market positioning.

• Chinese patent medicines (中成药)

  Traditional Chinese medicine products in prepared, patent form.

• 2024

  Guangyuyuan channel-stuffing and early revenue recognition; multiple financial reports found to contain false records

  The Shanxi Securities Regulatory Bureau found that Guangyuyuan recognized revenue early despite agreements allowing unconditional returns for slow-selling and near-expiry products, and that some sales expenses were miscalculated, causing false records in its annual reports from 2016 to 2022 and its 2023 half-year report. The penalty document imposed penalties on relevant responsible persons. Status: administrative penalty. Entities involved: Guangyuyuan Traditional Chinese Medicine Co., Ltd. and Shanxi Guangyuyuan Guoyao Co., Ltd.

  Source

• 2024

  Eight consecutive years of financial fraud; CSRC fines company RMB 8 million

  The CSRC found that Guangyuyuan Chinese Medicine Co., Ltd.'s 2016–2022 annual reports and 2023 half-year report contained false records, inflating performance by channel stuffing to distributors, recognizing revenue early, and shifting selling expenses across periods. Separately, its Guoyiguan advertisement claiming that Dingkundan “even severe menopause and amenorrhea fear this” was reported for suspected exaggeration of efficacy. The company was warned and fined RMB 8 million; former chairman Zhang Bin was subject to a 10-year market ban; the Shanghai Stock Exchange imposed disciplinary action.

  Source

Read more

1. 1Official website (URL supplied in subject)gyy.com.cn
2. 2Guangyuyuan channel-stuffing and early revenue recognition; multiple financial reports found to contain false recordscsrc.gov.cn
3. 3Eight consecutive years of financial fraud; CSRC fines company RMB 8 millioncsrc.gov.cn
4. 4Eight consecutive years of financial fraud; CSRC fines company RMB 8 millionbk.cnpharm.com